



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/594,455

06/22/2007

Michael Kretschmar

LNK-020

9277

31496 7590 01/12/2011
SMITH PATENT CONSULTING, LLC
515 East Braddock Road
Suite B
ALEXANDRIA, VA 22314

EXAMINER

KIM, ALEXANDER D

ART UNIT

PAPER NUMBER

1656

NOTIFICATION DATE

DELIVERY MODE

01/12/2011

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

chalin@smithpatent.com

Examiner-Initiated Interview Summary	Application No. 10/594,455	Applicant(s) KRETSCHMAR ET AL.	
	Examiner ALEXANDER D. KIM	Art Unit 1656	

All Participants:

 (1) ALEXANDER D. KIM.

 (2) Chalin Smith.
Status of Application: 80

(3) _____.

(4) _____.

Date of Interview: 22 December 2010
Time: 1PM
Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

 Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description: .

Part I.

Rejection(s) discussed:

N/A

Claims discussed:

All pending claims.

Prior art documents discussed:

N/A
Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

The Examiner has proposed amendment to instant claims as set forth below to proceed to an allowance.
Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

 /Alexander D Kim/
 Examiner, Art Unit 1656

(Applicant/Applicant's Representative Signature – if appropriate)

1. Canceled.
2. A process for purifying wild-type von Willebrand factor (VWF) from a plasma fraction comprising steps of:
 - (i) providing a sample of plasma fraction containing wild-type VWF and one or more contaminating proteins comprising fibronectin and/or fibrinogen;
 - (ii) preparing the sample of plasma fraction in a first running buffer at pH of 7.0-7.5 that consists essentially of 10-50 mM sodium and/or potassium phosphate,
 - (iii) performing flow chromatography by loading the sample of plasma fraction to a hydroxylapatite matrix under conditions that 90% or more of fibronectin and/or fibrinogen bind to the hydroxylapatite matrix, while at the same time, less than 10% of the wild-type VWF bind to the hydroxylapatite matrix thereby providing a flow through fraction(s) containing purified wild-type VWF, wherein the flow chromatography is performed with the first running buffer; and
 - (iv) purifying wild-type VWF by collecting unbound wild-type VWF from the flow through fraction(s).
- 3-6. Cancelled.
7. The process according to claim 2, further comprising step of:
 - (v) performing binding chromatography by loading the purified wild-type VWF to hydroxylapatite matrix under a condition such that the wild-type VWF is bound to a hydroxylapatite matrix and then subsequently eluted, wherein the flow chromatography is performed with a second running buffer at pH 5.5-6.8.
8. The process according to claim 7, wherein the step (v) comprises: (a) binding the wild-type VWF to the hydroxylapatite matrix, (b) washing out impurities, and (c) eluting the wild-type VWF thereby further purifying the wild-type VWF.
9. The process according to claim 8, wherein the step (a) is performed by the second running buffer with 1 to 200 mM sodium and/or potassium phosphate.
10. The process according to claim 8, wherein the step (b) is performed by the second running buffer with 100 to 300 mM sodium and/or potassium phosphate.
11. The process according to claim 8, wherein the step (c) is performed with the second running buffer with 200 to 500 mM sodium and/or potassium phosphate.
- 12-13. Cancelled.
14. The process according to claim 2, wherein the sample of plasma fraction in step (i) has been previously purified.
15. The process according to claim 2, wherein the sample of plasma fraction in step (i) comprises a separately purified cryoprecipitate solution.
16. The process according to claim 2, wherein the sample of plasma fraction in step (i) comprises a cryoprecipitate solution precipitated with aluminum hydroxide.
17. The process according to claim 2, wherein the sample plasma fraction in step (i) comprises a chromatographically pre-purified cryoprecipitate solution precipitated with aluminum hydroxide.
18. The process according to claim 2, further comprising the step of performing a pH precipitation prior to step of carrying out flow chromatography with hydroxylapatite matrix to separate fibronectin.
19. Canceled.
20. The process according to claim 2, wherein the hydroxylapatite is fluoroapatite.
- 21-24. Canceled.